Abstract
In the current issue of Circulation: Cardiovascular Genetics , Preuss and colleagues1 describe the design of the Coronary ARtery DIsease Genome-wide Replication And Meta-Analysis (CARDIoGRAM) consortium. CARDIoGRAM is one of several consortia that have formed in the past few years in order to combine data from different genome-wide association studies (GWAS) in large-scale metaanalyses. Many of these consortia have focused their efforts on traits from the cardiovascular and type 2 diabetes domains. In addition to CARDIoGRAM, other examples of trait-specific consortia in this field include the Meta-Analysis of Glucose and Insulin-Related Traits Consortium,2 the Global Lipids Genetics Consortium,3 the Diabetes Genetics Replication and Meta-analysis consortium,4 and the Genetic Investigation of Anthropometric Traits5 consortium. There are also examples of consortia that have a wider scope, with phenotypes ranging over the whole cardiovascular field, such as the Cohorts for Heart and Aging Research in Genomic Epidemiology (http://web.chargeconsortium.com/), European Network of Genomic and Genetic Epidemiology (http://www.euengage.org/), and Candidate Gene Association Resource6 consortia. The large-scale GWAS consortia have many things in common, such as: (1) rigorous and robust methods with greater statistical power than single-center studies, as exemplified in the current article from the CARDIoGRAM consortium; (2) researchers being involved in several consortia, leading to cross-fertilization, quicker development and implementation of new methods; and (3) study samples being used for different traits in different consortia for increased cost-effectiveness. Article see p 475 The development since the first successful example of a GWAS reporting an association between the CFH gene and age-related macular degeneration in 2005,7 via the landmark study from the Wellcome Trust Case Control Consortium in 2007,8 to the current situation has been quite remarkable. Independently of whether one thinks that the GWAS era has been a blessing or a burden for the cardiovascular genetics …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.